Ally Financial Inc vs Moderna, Inc. — how do they compare? Ally Financial Inc trades at $43.73 (market cap $13.37B), while Moderna, Inc. trades at $63.85 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Ally Financial Inc pays a 2.73% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ALLY | MRNA | |
|---|---|---|
Market Cap | $13.37B | $24.18B |
Sector | Financials | Health |
52-Week High | $47.25 | $81.80 |
52-Week Low | $35.96 | $22.36 |
Dividend Yield | 2.73% | — |
Enterprise Value | — | $20.33B |
Signals from Pluang's Aura AI — not financial advice
Ally Financial (ALLY) trades at $43.81, showing minimal daily movement. The stock exhibits a bearish technical signal with recent earnings missing estimates in Q2 2026, though revenue grew 10% year-over-year. Valuation metrics appear attractive with a P/E of 10.34 and P/B below 1. Analyst consensus remains strongly bullish with a $54.40 price target, but insider selling and mixed technical indicators suggest near-term caution.
The outlook for ALLY hinges on execution amid macroeconomic pressures. Upside potential exists from solid loan growth and digital banking strength, but risks include rising provisions, competitive pressures, and interest rate sensitivity. Earnings growth in upcoming quarters is critical for sustaining investor confidence and driving the stock toward analyst targets.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Trailing returns across standard periods
Ally Financial Inc is a diversified financial services firm that services automotive dealers and their retail customers. The company operates as a financial holding company and a bank holding company. Its banking subsidiary, Ally Bank, caters to the direct banking market through Internet, mobile, and mail. The company reports four business segments including Automotive Finance operations, Insurance operations, Mortgage Finance operations and Corporate Finance operations.
Read more on ALLY →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →